The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Dimerix (DXB) will raise $5.8 million to support its DMX-200 trials treating ARDS patients with COVID-19
  • The therapy drug is also being trialled in a kidney program to treat Focal Segmental Glomerulosclerosis
  • Over 16.2 million shares will be issued to institutions, as well as new and existing sophisticated and professional investors at a price of 36 cents each
  • The placement is expected to be settled and allocated either later this week or from next week
  • Company shares are down 11.4 per cent and trading for 39 cents each

Dimerix (DXB) will raise $5.8 million through a placement to institutions, as well as new and existing sophisticated and professional investors.

The placement will issue 16,222,580 fully paid ordinary shares at a price of 36 cents per share. This represents an 18.2 per cent discount to the last closing price of 44 cents on June 17 and a 9.4 per cent discount to the 15-day volume-weighted average price (VWAP).

The placement is expected to be settled and allocated either later this week or from next week.

The clinical-stage biopharmaceutical company will use the funds to support activities associated with the global REMAP-CAP study of DMX-200 in ARDS patients with COVID-19.

The funds will also go towards the next stage of development for the renal program, such as logistics and distribution costs, additional manufacturing scale-up costs, resource costs, general working capital and corporate costs.

“These funds will provide a solid runway to pursue the longer-term strategy, including the planning for the success of DMX-200 in the kidney program, as well as the ARDS associated with COVID-19 program,” CEO and Managing Director Dr Nina Webster said.

Last week, Dimerix dosed the final patient of its DMX-200 clinical trial which is treating Focal Segmental Glomerulosclerosis (FSGS). FSGS is a rare condition caused by scarring in the kidney which can cause kidney damage and failure.

This is one of two trials that is testing the DMX-200 therapy drug.

Since COVID-19, the company is investigating the potential of DMX-200 as a treatment for acute respiratory distress syndrome (ARDS) in patients with COVID-19.

Company shares are down 11.4 per cent and trading for 39 cents each at 11:58 am AEST.

DXB by the numbers
More From The Market Online
Nasal spray bottle generic

LTR Pharma’s SPONTAN ‘nasal viagra’ absorbed 470% times faster than oral solution

LTR Pharma (ASX:LTP) has posted final study results showing its 'nasal viagra' drug SPONTAN is absorbed…
The Market Online Video

Recce progresses testing of gel to treat bacterial skin infections

Recce Pharmaceuticals Ltd has reached an important milestone in testing of its R327G gel to treat…
Burn wound care

Orthocell wins first international approval for nerve repair product

West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences…
Map showing Valeriepieris Circle - a relatively small area of Earth’s surface that contains half the human population.

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical…